208 related articles for article (PubMed ID: 21777469)
1. Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study.
Jonsson L; Bergman J; Nodin B; Manjer J; Pontén F; Uhlén M; Jirström K
J Transl Med; 2011 Jul; 9():114. PubMed ID: 21777469
[TBL] [Abstract][Full Text] [Related]
2. High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma.
Nodin B; Fridberg M; Jonsson L; Bergman J; Uhlén M; Jirström K
Diagn Pathol; 2012 Jul; 7():82. PubMed ID: 22805320
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer.
Boman K; Segersten U; Ahlgren G; Eberhard J; Uhlén M; Jirström K; Malmström PU
BMC Urol; 2013 Apr; 13():17. PubMed ID: 23565664
[TBL] [Abstract][Full Text] [Related]
4. Low RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer.
Olofsson SE; Nodin B; Gaber A; Eberhard J; Uhlén M; Jirström K; Jerkeman M
PLoS One; 2015; 10(3):e0121300. PubMed ID: 25811459
[TBL] [Abstract][Full Text] [Related]
5. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
[TBL] [Abstract][Full Text] [Related]
6. High expression of RNA-binding motif protein 3 in esophageal and gastric adenocarcinoma correlates with intestinal metaplasia-associated tumours and independently predicts a reduced risk of recurrence and death.
Jonsson L; Hedner C; Gaber A; Korkocic D; Nodin B; Uhlén M; Eberhard J; Jirström K
Biomark Res; 2014; 2():11. PubMed ID: 24963396
[TBL] [Abstract][Full Text] [Related]
7. Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study.
Boman K; Andersson G; Wennersten C; Nodin B; Ahlgren G; Jirström K
Biomark Res; 2017; 5():10. PubMed ID: 28293425
[TBL] [Abstract][Full Text] [Related]
8. High RNA-Binding Motif Protein 3 (RBM3) Expression is Independently Associated with Prolonged Overall Survival in Intestinal-Type Gastric Cancer.
Ye F; Jin P; Cai X; Cai P; Cai H
Med Sci Monit; 2017 Dec; 23():6033-6041. PubMed ID: 29263314
[TBL] [Abstract][Full Text] [Related]
9. High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.
Jonsson L; Gaber A; Ulmert D; Uhlén M; Bjartell A; Jirström K
Diagn Pathol; 2011 Sep; 6():91. PubMed ID: 21955582
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity.
Wahlin S; Boman K; Moran B; Nodin B; Gallagher WM; Karnevi E; Jirström K
BMC Cancer; 2022 Feb; 22(1):131. PubMed ID: 35109796
[TBL] [Abstract][Full Text] [Related]
11. High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer.
Siesing C; Sorbye H; Dragomir A; Pfeiffer P; Qvortrup C; Pontén F; Jirström K; Glimelius B; Eberhard J
PLoS One; 2017; 12(8):e0182512. PubMed ID: 28800641
[TBL] [Abstract][Full Text] [Related]
12. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.
Svobodová S; Browning J; MacGregor D; Pollara G; Scolyer RA; Murali R; Thompson JF; Deb S; Azad A; Davis ID; Cebon JS
Eur J Cancer; 2011 Feb; 47(3):460-9. PubMed ID: 21115342
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of galectin-3 in primary cutaneous melanoma.
Buljan M; Šitum M; Tomas D; Milošević M; Krušlin B
J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1174-81. PubMed ID: 21175876
[TBL] [Abstract][Full Text] [Related]
14. Incident urothelial cancer in the Malmö Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker.
Wennersten C; Andersson G; Boman K; Nodin B; Gaber A; Jirström K
Diagn Pathol; 2014 Oct; 9():189. PubMed ID: 25278252
[TBL] [Abstract][Full Text] [Related]
15. HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome.
Bengtsson E; Nerjovaj P; Wangefjord S; Nodin B; Eberhard J; Uhlén M; Borgquist S; Jirström K
Diagn Pathol; 2014 Apr; 9():78. PubMed ID: 24708688
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of RBM3 expression in surgically treated colorectal lung metastases and paired primary tumors.
Vidarsdottir H; Siesing C; Nodin B; Jönsson P; Eberhard J; Jirström K; Brunnström H
J Surg Oncol; 2021 Mar; 123(4):1144-1156. PubMed ID: 33497473
[TBL] [Abstract][Full Text] [Related]
17. Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.
Jögi A; Brennan DJ; Rydén L; Magnusson K; Fernö M; Stål O; Borgquist S; Uhlen M; Landberg G; Påhlman S; Pontén F; Jirström K
Mod Pathol; 2009 Dec; 22(12):1564-74. PubMed ID: 19734850
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
Bauer R; Wild PJ; Meyer S; Bataille F; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
J Clin Pathol; 2006 Jul; 59(7):699-705. PubMed ID: 16565225
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of RNA binding motif protein 3 (RBM3) in non-small cell lung cancer.
Salomonsson A; Micke P; Mattsson JSM; La Fleur L; Isaksson J; Jönsson M; Nodin B; Botling J; Uhlén M; Jirström K; Staaf J; Planck M; Brunnström H
Cancer Med; 2020 Aug; 9(15):5609-5619. PubMed ID: 32491279
[TBL] [Abstract][Full Text] [Related]
20. Metallothionein-overexpression as a prognostic factor for progression and survival in melanoma. A prospective study on 520 patients.
Weinlich G; Bitterlich W; Mayr V; Fritsch PO; Zelger B
Br J Dermatol; 2003 Sep; 149(3):535-41. PubMed ID: 14510986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
